Company Filing History:
Years Active: 2014-2018
Title: Neil C. Faiber: Innovating at the Intersection of Pharmaceuticals and Patents
Introduction
Neil C. Faiber, an accomplished inventor based in Arlington, MA, has made significant contributions to the field of pharmaceuticals. With a robust portfolio that includes two patents, Faiber's work is instrumental in advancing medical treatments, particularly those addressing conditions mediated by Aurora kinase.
Latest Patents
Neil C. Faiber's latest innovations include two remarkable patents centered around a compound of formula (I): sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate. The patents pertain to the compound itself, its crystalline forms, and its solvates, emphasizing its efficacy in treating patients suffering from diseases, disorders, or conditions associated with Aurora kinase. These patents also cover solid pharmaceutical compositions that incorporate the compound, offering hope for significant medical advancements.
Career Highlights
Neil C. Faiber is affiliated with Millennium Pharmaceuticals Limited, a prominent entity in the pharmaceutical industry. His career is marked by a commitment to innovation and the development of novel therapeutic approaches that align with the company's mission of improving patient outcomes.
Collaborations
Throughout his career, Faiber has collaborated with notable colleagues, including Ian G. Armitage and Martin Ian Cooper. These partnerships have likely played a pivotal role in enriching Faiber's research and fostering innovative solutions in the realm of pharmaceuticals.
Conclusion
Neil C. Faiber stands out as a brilliant inventor in the pharmaceutical sector, his work significantly contributing to the development of treatments for challenging medical conditions. With his two patents, Faiber exemplifies the spirit of innovation that drives progress in healthcare, affirming his position as a valuable asset to Millennium Pharmaceuticals Limited and the broader scientific community.